WHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout

Pharmaceutical Technology· July 3, 2026

The World Health Organization (WHO) has announced an intensification of its efforts to combat Ebola through the implementation of new drug trials and the rollout of diagnostic resources. This strategic move aims to enhance the clinical management of the disease while improving the speed and accuracy of case detection in affected areas. For the pharmaceutical industry, these initiatives provide a framework for testing the real-world efficacy of experimental treatments and diagnostic kits under emergency conditions.

Read the full story at Pharmaceutical Technology

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Pharmaceutical Technology.

More in Pharmaceutical

Judge suspends Colorado's price cap on prescription drug Enbrel while lawsuit plays out

A federal judge has issued a preliminary injunction blocking Colorado’s attempt to cap the price of Amgen’s arthritis medication, Enbrel, marking a significant legal development for the pharmaceutical industry. The ruling by Judge Daniel Domenico suggests that the state's Prescription Drug Affordability Board (PDAB) likely overstepped its authority by interfering with federal patent laws. This decision stalls the first-ever price cap set by the board and creates a critical precedent as other states look to implement similar drug-pricing regulations.

July 3, 2026

Fritts to host prescription drug drop-off event in Rochelle July 16

State Representative Bradley Fritts (R-Dixon) will host a prescription drug drop-off event on July 16 in Rochelle to facilitate the safe disposal of expired or unwanted medications. The event is a partnership between the representative’s office, the Ogle County Health Department, and the Rochelle Police Department. For the pharmaceutical sector, these initiatives are essential for promoting responsible medication management and preventing the environmental and social risks associated with improper drug disposal.

July 3, 2026

Arthur Cox advises on pharmaceutical sector acquisition

Arthur Cox advises on pharmaceutical sector acquisition ICLG

July 3, 2026

Vertex Pharmaceuticals Wins FDA Approval to Treat Two-Year-Olds With CASGEVY

The U.S. Food and Drug Administration has granted expanded approval for Vertex Pharmaceuticals’ gene therapy, CASGEVY, to include children as young as two years old. This regulatory milestone allows the treatment to be used for pediatric patients suffering from sickle cell disease and transfusion-dependent beta thalassemia. The expansion is significant for the pharmaceutical sector as it establishes CASGEVY as the first gene therapy of its kind available to this specific age group in the United States, potentially reaching thousands of new patients.

July 3, 2026